CLINICAL TRIALS PROFILE FOR FLUOROMETHOLONE

All Clinical Trials for fluorometholone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00707421 ↗	Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes	Completed	Funding for Research in Ophthalmology (FRO)	Phase 3	2005-07-01	Antiglaucoma medication have been shown to induce subclinical conjunctival inflammation in a considerable proportion of glaucoma patients. Today, trabeculectomy still remains the gold standard as surgical treatment of medically uncontrolled glaucoma disease. However, this procedure is associated with variable possible complications, of which subconjunctival fibrosis is the most frequent one. The latter results in a non-functional filtering bleb. As a consequence, either additional interventions such as laser suture lysis, needling, bleb revision or additional IOP-lowering medication is necessary. Previous studies demonstrated a benefit of the use of topical steroids postoperatively in reducing inflammation and subsequent subconjunctival fibrosis. In this perspective, we will prospectively explore the usefulness of topical NSAID or corticosteroid therapy preoperatively as compared to placebo in subjects scheduled for first-time trabeculectomy, without interrupting topical antiglaucoma therapy. This will allow us to determine wether the impact of longterm topical antiglaucoma therapy on subclinical conjunctival inflammation which possibly result in postoperative fibrosis and bleb failure can be reversed by anti-inflammatory medication before filtering surgery.
NCT00707421 ↗	Usefulness of Topical Non-Steroidal Anti-Inflammatory Drugs or Steroids Before Trabeculectomy and Clinical Outcomes	Completed	Universitaire Ziekenhuizen Leuven	Phase 3	2005-07-01	Antiglaucoma medication have been shown to induce subclinical conjunctival inflammation in a considerable proportion of glaucoma patients. Today, trabeculectomy still remains the gold standard as surgical treatment of medically uncontrolled glaucoma disease. However, this procedure is associated with variable possible complications, of which subconjunctival fibrosis is the most frequent one. The latter results in a non-functional filtering bleb. As a consequence, either additional interventions such as laser suture lysis, needling, bleb revision or additional IOP-lowering medication is necessary. Previous studies demonstrated a benefit of the use of topical steroids postoperatively in reducing inflammation and subsequent subconjunctival fibrosis. In this perspective, we will prospectively explore the usefulness of topical NSAID or corticosteroid therapy preoperatively as compared to placebo in subjects scheduled for first-time trabeculectomy, without interrupting topical antiglaucoma therapy. This will allow us to determine wether the impact of longterm topical antiglaucoma therapy on subclinical conjunctival inflammation which possibly result in postoperative fibrosis and bleb failure can be reversed by anti-inflammatory medication before filtering surgery.
NCT00824811 ↗	Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel	Withdrawn	Allergan	Phase 2	2009-06-01	Objective: To evaluate the safety and efficacy of topical cyclosporine eye drops (Restasis®) for the treatment of epiphora caused by canalicular stenosis secondary to Docetaxel (Taxotere®) treatment for various cancers.
NCT00824811 ↗	Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel	Withdrawn	M.D. Anderson Cancer Center	Phase 2	2009-06-01	Objective: To evaluate the safety and efficacy of topical cyclosporine eye drops (Restasis®) for the treatment of epiphora caused by canalicular stenosis secondary to Docetaxel (Taxotere®) treatment for various cancers.
NCT01288404 ↗	Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium	Completed	Ramathibodi Hospital	N/A	2008-01-01	Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.

Clinical Trial Conditions for fluorometholone

Condition Name

Condition Name for fluorometholone
Intervention	Trials
Intraocular Pressure	4
Trichiasis	2
Dexamethasone Adverse Reaction	1
Fuchs Dystrophy	1

Condition MeSH

Condition MeSH for fluorometholone
Intervention	Trials
Keratoconjunctivitis Sicca	3
Eye Diseases	3
Dry Eye Syndromes	3
Keratoconjunctivitis	3

Clinical Trial Locations for fluorometholone

Trials by Country

Trials by Country for fluorometholone
Location	Trials
China	4
United States	3
Ethiopia	2
Egypt	2
United Kingdom	1

Trials by US State

Trials by US State for fluorometholone
Location	Trials
Indiana	2
Utah	1

Clinical Trial Progress for fluorometholone

Clinical Trial Phase

Clinical Trial Phase for fluorometholone
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	3
Phase 2	4

Clinical Trial Status

Clinical Trial Status for fluorometholone
Clinical Trial Phase	Trials
Completed	11
Not yet recruiting	5
Unknown status	3

Clinical Trial Sponsors for fluorometholone

Sponsor Name

Sponsor Name for fluorometholone
Sponsor	Trials
University of Pennsylvania	2
Price Vision Group	2
Berhan Public Health and Eye Care Consultancy PLC	2

Sponsor Type

Sponsor Type for fluorometholone
Sponsor	Trials
Other	33
Industry	4
U.S. Fed	1